



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 19-01-2011

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL
DESIGNS FOR THE WEEK-ENDING OF 08-01-2011 TO BE
PUBLISHED 24-01-2011 IN THE GAZETTE OF PAKISTAN PART-
V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

Sd/-
(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL: Nine pages only.

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

03-01-2011

- | | | |
|---------|--|--|
| 02/2011 | Honda Motor Co., Ltd.,
Japan
(Priority 28-02-2010 Japan) | “Cowl structure of saddle-ride type vehicle” |
| 03/2011 | Haider Ejaz,
Karachi,
Pakistan | “Heavy dust cleaner” |

04-01-2011

- | | | |
|---------|--|--|
| 04/2011 | Lurgi GmbH.,
Germany
(Priority 09-02-2010 Germany) | “Port arrangement for an internal component” |
|---------|--|--|

06-01-2011

- | | | |
|---------|--|---|
| 05/2011 | Sanofi-Aventis,
France
(Priority 08-01-2010 Hungary) | “New Process for the preparation of dronedarone” |
| 06/2011 | Janssen Pharmaceutical N.V.,
Belgium
(Priority 11-01-2010 USA) | “Pro-drugs of (e)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid” |

07-01-2011

- | | | |
|---------|---|---|
| 07/2011 | Takeda Pharmaceutical
Company Limited,
Japan
(Priority 08-01-2010 GB) | “Compounds and their use” |
| 08/2011 | Sanofi-Aventis,
France
(Priority 08-01-2010 France) | “5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, preparation thereof and therapeutic use thereof” |
| 09/2011 | Syed Hassan Javed,
Shahid Naveed,
Muhammad Mansha,
Lahore,
Pakistan | “Belite Cement from Rice Husk” |

08-01-2011

10/2011	Eurand,Inc., USA (Priority 08-01-2010 USA)	“Tasted masked topiramate composition and an orally disintegrating tablet comprising the same”
11/2011		(WITHDRAWN)
12/2011		(WITHDRAWN)

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

1142/2001	Janssen Alzheimer Immunotherapy and Wyeth, USA	"Humanized Antibodies That Recognise Beta Amyloid Peptide" CO7K 15/28, C12P 21/08
-----------	--	---

141085

A humanized immunoglobulin which specifically binds beta amyloid peptide (A β), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising:

- (i) a light chain comprising complementarity determining regions (CDRs) from the 3D6 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:2, and a variable framework region substantially from a human acceptor immunoglobulin light chain sequence; and
- (ii) a heavy chain comprising complementarity determining regions (CDRs) from the 3D6 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:4, and a variable framework region substantially from a human acceptor immunoglobulin heavy chain.

817/2005

Titan Paints & Chemicals Ltd., “Rotating bobbin holder”
India

D01H 1/18

141086

A rotating bobbin holder comprising a stud member with a head, a body of variable length and with a substantially non-circular cross section, said body further extended as a threaded profile, said stud member disposed to pass through a smaller opening of the expanded barrel, a brake shoe permitted to pass through said stud member and disposed on the outer-upper surface of the barrel to provide a variable a brake force by means of a brake tensioner, said tensioner connected to the brake shoe on one side and the other side of the tensioner is abutted by a tensioner support member, a skirt member is permitted to pass through the stud member and disposed on the upper extended barrel, a relative surface profile on top inner surface of the skirt member corresponding to the outer profile of the tensioner support member to provide a non-rotatable functional support to the skirt member, and at least a spacer member disposed on the body of the stud member to compress and decompress said tensioner and to generate variable braking force on said bobbin hanging tube.

1183/2006

Janssen Alzheimer
Immunotherapy and Wyeth,
USA

“A humanized immunoglobulin, or antigen-binding fragment thereof”

A61K 39/395, C12P 21/08

141087

A humanized immunoglobulin, or antigen-binding fragment thereof, which specifically binds to beta amyloid peptide (A β) with a binding affinity of at least 10^7 M⁻¹, comprising (i) a light

chain comprising at least one variable region complementarity determining region (CDR) from the 3D6 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:2, and a variable framework region from a human acceptor immunoglobulin light chain sequence, and (ii) a heavy chain comprising at least one variable region CDR from the 3D6 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:4, and a variable framework region from a human acceptor immunoglobulin heavy chain, provided that the humanized immunoglobulin, or antigen-binding fragment thereof, comprises:

- (a) at least one substitution of a canonical framework residue selected from the group consisting of L2, L48, L64, L71, H24, H26, H27, H29, H71, and H94 (Kabat numbering convention),
- (b) at least one substitution of an interchain packing framework residue selected from the group consisting of L36, L38, L44, L46, L87, L98, H37, H39, H45, H47, H91, H93, and H103 (Kabat numbering convention), and
- (c) at least one substitution of a vernier zone framework residue selected from the group consisting of L4, L35, L47, L49, L66, L68, L69, H2, H28, H30, H48, H49, H67, H69, and H80 (Kabat numbering convention), or at least one substitution of a rare framework residue selected from the group consisting of L1, L15, L83, L85, H40 and H42 (Kabat numbering convention), wherein the substitution is with the corresponding amino acid residue from the mouse 3D6 light chain variable region sequence or the mouse 3D6 heavy chain variable region sequence.

1184/2006

Janssen Alzheimer
Immunotherapy and Wyeth,
USA

"A humanized immunoglobulin which specifically binds beta amyloid peptide(AB)"

CO7K 16/00

141088

A humanized immunoglobulin which specifically binds beta amyloid peptide (A β), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising:

- (i) a light chain comprising complementarity determining regions (CDRs) from the 10D5 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:14, and a variable framework region substantially from a human acceptor immunoglobulin light chain sequence; and
- (ii) a heavy chain comprising complementarity determining regions (CDRs) from the 10D5 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:16, and a variable framework region substantially from a human acceptor immunoglobulin heavy chain.

1554/2006 Life Technologies Private Limited,
Lahore,
Pakistan

“Method for producing an improved and multipurpose fertilizer for soils which are alkaline and low in organic mater”

C05C 9/00

141089

A method for producing an improved fertilizer composition especially suited for soils which are alkaline and low in organic matter. The composition consists of reaction product at low H₂SO₄/Urea molar ratio of 0.30 but is potentiated with fulvic acid which enhances efficacy of both nitrogen and sulfur nutrients by improving their uptake by plants.

624/2007 Graf + Cie AG.,
Switzerland

“Toothed clothing for a comb of a combing machine”

141090

Toothed clothing for a comb of a combing machine as well a process for producing same is described. The toothed clothing comprises a plurality of adjacently arranged teeth, which form at least one teeth row orientated transversely to the working direction. The teeth of the clothing are formed from the solid and are made in one piece to form a tooth bar. In addition, a top comb and a circular comb for a combing machine having such toothed clothings are also described. The toothed clothings hereby comprise one or more teeth rows.

253/2009

Novartis AG.,
Switzerland

“Substituted 1h-imidazolyl-
pyrimidinylaminoethyl-2-
Methoxyacetamide compound”

CO7D 401/14, CO7D 471/04, CO7D
413/14, A61P 35/00

141091

Disclosed is a new compound of
Formula I



and composition containing it. The new compound and composition may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

891/2009

Unilever PLC.,
United Kingdom

“An aqueous coagulant composition for water purification comprising aluminium salt, Iron salt and potassium permanganate”

CO2F 1/50, CO2F 1/62, CO2F 1/52

141092

The invention relates to a water purification composition. The invention particularly relates to a water purification composition that is especially useful for removal of trace quantities of harmful heavy-metal contaminants like Arsenic, in addition to removal of micro-organisms like viruses, bacteria and cysts to make the water suitable for human consumption.

It is an object of the present invention to provide a coagulant composition for purification of water that provides for removal of at least 90% Arsenic, and 6-log bacteria, 4-log virus and 2-log cysts from contaminated water.

The present inventors have found that an aqueous composition which includes Aluminium salt; Iron salt; Potassium permanganate, in define ratios meet the above objects.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>08-01-2011</u>			
1)	150102	Pressure Regulator (Class-01)	Cavagna Group S.p.A.

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>03-01-2011</u>			
1)	14956	Reagent Container (Class-03)	Sysmex Corporation
2)	15032	Bottle (Class-03)	PepsiCo, Inc
3)	15052	Plastic Bottle Cap (Class-03)	Print Pack

Sd/-
(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056